TrialClinical cancer research : an official journal of the American Association for Cancer Research2026

A Phase II Study of Docetaxel and Pembrolizumab plus Interleukin 12 Gene Therapy in Nonmetastatic, Anthracycline-Refractory Triple-Negative Breast Cancer (INTEGRAL).

Polly Niravath et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.